EGFR and non-small cell lung carcinoma: In conclusion, this study showcased an improved OS of EGFR-TKI plus bevacizumab in a real-world cohort of patients with advanced EGFR-mutant NSCLC in which patients with brain metastasis received most benefit from the regimen.